JP2017538659A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538659A5
JP2017538659A5 JP2017512982A JP2017512982A JP2017538659A5 JP 2017538659 A5 JP2017538659 A5 JP 2017538659A5 JP 2017512982 A JP2017512982 A JP 2017512982A JP 2017512982 A JP2017512982 A JP 2017512982A JP 2017538659 A5 JP2017538659 A5 JP 2017538659A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
tumor
group
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538659A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049221 external-priority patent/WO2016040505A1/en
Publication of JP2017538659A publication Critical patent/JP2017538659A/ja
Publication of JP2017538659A5 publication Critical patent/JP2017538659A5/ja
Pending legal-status Critical Current

Links

JP2017512982A 2014-09-10 2015-09-09 Ｓｍｙｄ阻害剤 Pending JP2017538659A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048773P 2014-09-10 2014-09-10
US62/048,773 2014-09-10
US201562146799P 2015-04-13 2015-04-13
US62/146,799 2015-04-13
PCT/US2015/049221 WO2016040505A1 (en) 2014-09-10 2015-09-09 Smyd inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020013314A Division JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤

Publications (2)

Publication Number Publication Date
JP2017538659A JP2017538659A (ja) 2017-12-28
JP2017538659A5 true JP2017538659A5 (enExample) 2018-10-18

Family

ID=55459528

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512982A Pending JP2017538659A (ja) 2014-09-10 2015-09-09 Ｓｍｙｄ阻害剤
JP2020013314A Pending JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤
JP2022118248A Pending JP2022163087A (ja) 2014-09-10 2022-07-25 Ｓｍｙｄ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020013314A Pending JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤
JP2022118248A Pending JP2022163087A (ja) 2014-09-10 2022-07-25 Ｓｍｙｄ阻害剤

Country Status (13)

Country Link
US (4) US10266526B2 (enExample)
EP (1) EP3193600A4 (enExample)
JP (3) JP2017538659A (enExample)
KR (2) KR20230026515A (enExample)
CN (2) CN107072205B (enExample)
AU (1) AU2015315174B2 (enExample)
BR (1) BR112017004612A2 (enExample)
CA (1) CA2960275A1 (enExample)
EA (1) EA201790317A1 (enExample)
IL (2) IL250891A0 (enExample)
MX (2) MX2017002985A (enExample)
SG (2) SG10201901192TA (enExample)
WO (1) WO2016040505A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2016040502A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted cyclohexylamine compounds
JP2017528464A (ja) 2014-09-10 2017-09-28 エピザイム，インコーポレイティド 置換ピペリジン化合物
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
WO2018030550A1 (en) 2016-08-09 2018-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds with an ror(gamma)t modulating activity
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
BR112019018691A2 (pt) 2017-03-10 2020-04-07 Rutgers, The State University Of New Jersey derivados de indol como inibidores de bomba de efluxo
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
JP2020524717A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
KR20200052294A (ko) 2017-08-14 2020-05-14 에피자임, 인코포레이티드 Setd2의 저해에 의한 암의 치료 방법
CN112585119A (zh) * 2018-08-14 2021-03-30 Epizyme股份有限公司 经取代的吲哚及其使用方法
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
CN114450006B (zh) * 2019-08-08 2025-10-14 斯特拉斯堡大学 TrkB正别构调节剂
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
MX2022007171A (es) * 2019-12-27 2022-08-22 Schroedinger Inc Compuestos cíclicos y métodos de uso de estos.
AU2021224855A1 (en) * 2020-02-19 2022-09-08 Epizyme, Inc. SETD2 inhibitors and related methods and uses, including combination therapies
WO2021257544A1 (en) 2020-06-16 2021-12-23 Icahn School Of Medicine At Mount Sinai Sox11 inhibitors for treating mantle cell lymphoma
CA3204318A1 (en) 2020-12-17 2022-06-23 Astrazeneca Ab N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
CN114246851B (zh) * 2021-11-09 2024-01-26 澳门科技大学 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途
CN114702552B (zh) * 2022-03-11 2024-05-31 苏州思萃免疫技术研究所有限公司 mTORC2抑制剂
WO2023192665A2 (en) * 2022-04-01 2023-10-05 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
GB2620976B (en) * 2022-07-28 2024-07-24 Jones Paul Amido-amine hardener
EP4618978A1 (en) * 2022-11-17 2025-09-24 Tenvie Therapeutics Inc. Compounds, compositions, and methods
EP4618979A2 (en) * 2022-11-17 2025-09-24 Tenvie Therapeutics Inc. Compounds, compositions, and methods
WO2024158863A1 (en) * 2023-01-25 2024-08-02 The Rockefeller University Sulfonamide-1h-pyrrole-2-carboxamide inhibitors of sars-cov-2 nsp14 methyltransferase and derivatives thereof
CN116327748B (zh) * 2023-04-21 2024-09-17 武汉科技大学 联合用药物在制备抗肿瘤药物中的用途
WO2025165834A1 (en) * 2024-01-31 2025-08-07 Ensem Therapeutics, Inc. Urea derivatives of tricyclic compounds, and compositions and methods thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1441195A (en) * 1993-12-30 1995-07-17 Smithkline Beecham Corporation Phenylmethyl hexanamides, and the use thereof
AU4966497A (en) * 1996-11-18 1998-06-10 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
CN1391562A (zh) * 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2002006249A1 (en) 2000-07-19 2002-01-24 Takeda Chemical Industries, Ltd. Method for producing 1-substituted-1,2,3-triazole derivative
AUPR034000A0 (en) * 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
CA2443108A1 (en) * 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
JP2004175739A (ja) * 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd 医薬組成物
JP2004315395A (ja) * 2003-04-14 2004-11-11 Yamanouchi Pharmaceut Co Ltd 新規な安息香酸誘導体又はその塩
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
ES2530972T3 (es) * 2003-09-12 2015-03-09 Elixir Pharmaceuticals Inc Métodos de tratamiento de trastornos
WO2005073224A2 (en) * 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
CA2555812A1 (en) * 2004-02-13 2005-09-01 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP2008520742A (ja) * 2004-11-23 2008-06-19 ピーティーシー セラピューティクス， インコーポレイテッド Ｖｅｇｆ産生の阻害に有用なカルバゾール誘導体、カルボリン誘導体およびインドール誘導体
CN101171250A (zh) * 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 具有抗菌活性的氮杂环丁烷和吡咯的三环衍生物
MX2007012448A (es) * 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
US7273882B2 (en) * 2005-06-21 2007-09-25 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as β-secretase inhibitors
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
DOP2006000273A (es) * 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
CA2657660A1 (en) * 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
WO2008016666A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
EP2121626A1 (en) * 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
PE20091576A1 (es) * 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
CA2724430A1 (en) * 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
CA2724998A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
CA2735593C (en) * 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
ES2552462T3 (es) * 2010-10-14 2015-11-30 Jw Pharmaceutical Corporation Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
AU2011338302A1 (en) * 2010-12-08 2013-07-11 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use
EP2532661A1 (en) * 2011-06-10 2012-12-12 Syngenta Participations AG Novel insecticides
ES2596369T3 (es) * 2011-06-17 2017-01-09 Basilea Pharmaceutica Ag Antibióticos N-heterotricíclicos
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
CN103877078B (zh) * 2012-12-20 2017-03-15 上海交通大学医学院 Senp2小分子抑制剂及其应用
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
JP2017528464A (ja) 2014-09-10 2017-09-28 エピザイム，インコーポレイティド 置換ピペリジン化合物
JP2017528461A (ja) 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 置換ピロリジンカルボキサミド化合物
WO2016040502A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted cyclohexylamine compounds
US20170253601A1 (en) 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds

Similar Documents

Publication Publication Date Title
JP2017538659A5 (enExample)
JP2020090520A5 (enExample)
JP2017528461A5 (enExample)
JP2017511801A5 (enExample)
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2017528464A5 (enExample)
US10889589B2 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
US9546156B2 (en) N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
AU2015330506B2 (en) EGFR inhibitor, and preparation and application thereof
US9969694B2 (en) N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
JP2020503299A5 (enExample)
CN112601747B (zh) 作为malt1抑制剂的吡唑衍生物
JP2011510995A5 (enExample)
JP2017538659A (ja) Ｓｍｙｄ阻害剤
WO2014078325A1 (en) N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en) Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
JP2019519595A (ja) 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物
MXPA05007990A (es) Compuestos de tienopirimidina y uso de los mismos.
CA3274821A1 (en) N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES USED AS WILD-TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA
JP2017528460A5 (enExample)
CN104098551A (zh) 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
JP2017526706A5 (enExample)
JP2017527577A (ja) 置換ピロリジン化合物